The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N-alpha-(4-amino-4-deoxypteroyl)-N-delta-hemiphthaloyl-L-ornithine
A. Rosowsky et al., The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N-alpha-(4-amino-4-deoxypteroyl)-N-delta-hemiphthaloyl-L-ornithine, PHARM THERA, 85(3), 2000, pp. 191-205
N-alpha-(4-Amino-4-deoxypteroyl)-N-delta-hemiphthaloyl-L-ornithine (PT523)
is an unusually tight-binding dihydrofolate reductase (DHFR) inhibitor and
is efficiently taken up into cells via the reduced folate carrier (RFC). Un
like classical DHFR inhibitors with a glutamate side chain, such as methotr
exate and aminopterin, PT523 cannot form polyglutamates, Thus, it resembles
lipophilic antifolates such as trimetrexate in not requiring metabolic act
ivation by folylpolyglutamate synthetase in order to produce its antifolate
effect. However, in contrast to trimetrexate, PT523 retains growth inhibit
ory activity in cells with the multidrug resistance phenotype. As part of t
he preclinical development of this drug, we have performed systematic modif
ication of several regions of the PT523 molecule, with the aim of defining
the optimal structural features for DHFR binding, influx into cells via the
RFC, and the ability to inhibit cell growth. The following structure-activ
ity correlations have emerged from this ongoing investigation, and are disc
ussed: (1) the hemiphthaloylornithine side chain has the optimal length; (2
) the preferred location of the aromatic carboxyl group is the ortho positi
on; and (3) replacement of the phenyl ring of the para-aminobenzoic acid mo
iety by naphthalene, of nitrogen at the 10-position of the bridge by carbon
, and of nitrogen at the 5- and/or 8-position of the B-ring by carbon are a
ll well tolerated, Several of the second generation analogs of PT523 are mo
re potent DHFR inhibitors and better RFC substrates than PT523 itself, and
are more potent inhibitors of tumor cell growth in culture. (C) 2000 Elsevi
er Science Inc, All rights reserved.